Quantcast

Industry news that matters to you.  Learn more

Archives for June 2015

U-M Health System Launches $160M Project to Improve Lab Tests for Patients in Michigan and Beyond

Millions of times a year, teams at the University of Michigan Health System test samples of tissue, blood and other bodily fluids for patients of all ages. The results can reveal risks or signs of disease — or response to treatment — and help make a major difference in doctors’ decisions.

OncoCyte Announces Initial Data From Ongoing Clinical Study of Collagen Type X as a Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation recently announced initial data from a large, prospective clinical study that showed the potential of PanC-Dx™, OncoCyte’s non-invasive diagnostic technology based on its proprietary set of cancer markers, as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data showed the utility of the protein Collagen Type X (COL10A1) in distinguishing patients with malignant breast lesions from those with negative findings. The clinical data was presented by Maria Prendes, PhD, Director of Manufacturing at OncoCyte, at the American Association for Cancer Research (AACR) Annual Meeting during a poster presentation from 8:00 AM -12:00 PM EDT on Monday, April 20, 2015.

PPD Laboratories Opens Central Lab in Shanghai, China

Pharmaceutical Product Development, LLC (PPD) has opened a central laboratory in Shanghai, China, to deliver global scientific and technical laboratory expertise to meet growing client demand for these services in China. The new facility, which has been established in association with Shanghai Clinical Research Center (SCRC), is equipped with cutting-edge analytical equipment to provide high-quality data across a wide range of technologies and applications for all phases of pharmaceutical development.

Transgenomic Launches New Multiplexed Ice-Cold PCR Service in Biomarker Identification Business

Transgenomic, Inc. (NASDAQ: TBIO) recently announced that its groundbreaking Multiplexed ICE COLD PCR™ (MX-ICP) technology is now available to pharmaceutical and biotechnology customers of the company’s Biomarker Identification business unit. MX-ICP is an ultra- high sensitivity DNA amplification technology that allows the detection of multiple mutations in multiple genes from any sample, either from a tumor biopsy or from liquids such as blood or urine. MX-ICP is validated and available for use on all sequencing platforms.

Biodesix Launches GeneStrat Targeted Liquid Biopsy Mutation Test For Patients With Advanced Lung Cancer

Biodesix, Inc. recently announced the launch of GeneStrat™, a targeted liquid biopsy mutation test for genotyping tumors of patients with advanced non-small cell lung cancer (NSCLC). The blood test results are available within 72 hours, providing physicians actionable diagnostic information prior to making treatment decisions. GeneStrat is focused exclusively on the clinically actionable EGFR, KRAS, and BRAF mutations often used to guide targeted therapy treatment decisions. GeneStrat also captures the EGFR T790M mutation, which can be used for monitoring the emergence of the primary resistance mutation in the EGFR gene. It is anticipated that two drugs targeting the resistance mutation may be available later this year. GeneStrat uses the ddPCR platform to analyze cell-free tumor DNA and is highly concordant with tissue analysis, currently considered the gold standard.